acc1751 |
ERK1 |
phosphorylation |
Thr202 |
human |
Hepatocellular Carcinoma |
HepG2 |
Isofraxidin |
Associated |
4.0 |
20930381
|
acc1752 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
HepG2 |
Isofraxidin |
Associated |
4.0 |
20930381
|
acc1753 |
ERK2 |
phosphorylation |
Thr185 |
human |
Hepatocellular Carcinoma |
HepG2 |
Isofraxidin |
Associated |
4.0 |
20930381
|
acc1754 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Hepatocellular Carcinoma |
HepG2 |
Isofraxidin |
Associated |
4.0 |
20930381
|
acc1755 |
BAD |
phosphorylation |
Ser75 |
human |
Melanoma |
A2058 |
Sorafenib |
Associated |
4.0 |
16452220
|
acc1756 |
BAD |
phosphorylation |
Ser99 |
human |
Melanoma |
A2058 |
Sorafenib |
Associated |
4.0 |
16452220
|
acc1757 |
BAD |
phosphorylation |
Ser75 |
human |
Melanoma |
SK-MEL-5 |
Sorafenib |
Associated |
4.0 |
16452220
|
acc1758 |
BAD |
phosphorylation |
Ser99 |
human |
Melanoma |
SK-MEL-5 |
Sorafenib |
Associated |
4.0 |
16452220
|
acc1759 |
EZH2 |
phosphorylation |
Ser21 |
human |
Breast Cancer |
MCF7 |
Tamoxifen |
Impairing |
5.0 |
36356296
|
acc1760 |
FAK |
phosphorylation |
Tyr925 |
human |
Meningioma |
IOMM-Lee |
pUC |
Associated |
4.0 |
21347260
|
acc1761 |
FAK |
phosphorylation |
Tyr925 |
human |
Meningioma |
CH-157MN |
pUC |
Associated |
4.0 |
21347260
|
acc1762 |
FAK |
phosphorylation |
Tyr397 |
human |
Glioma |
LN229 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1763 |
IGF-IR |
phosphorylation |
Tyr1135 |
human |
Glioma |
LN229 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1764 |
IGF-IR |
phosphorylation |
Tyr1136 |
human |
Glioma |
LN229 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1765 |
FAK |
phosphorylation |
Tyr397 |
human |
Glioma |
U87 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1766 |
IGF-IR |
phosphorylation |
Tyr1135 |
human |
Glioma |
U87 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1767 |
IGF-IR |
phosphorylation |
Tyr1136 |
human |
Glioma |
U87 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1768 |
FAK |
phosphorylation |
Tyr397 |
human |
Glioma |
U251 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1769 |
IGF-IR |
phosphorylation |
Tyr1135 |
human |
Glioma |
U251 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1770 |
IGF-IR |
phosphorylation |
Tyr1136 |
human |
Glioma |
U251 |
TAE226 |
Associated |
4.0 |
17431114
|
acc1771 |
c-Myc |
phosphorylation |
Ser62 |
human |
Cholangiocarcinoma |
QBC939 |
PD98059 |
Associated |
4.0 |
20101459
|
acc1772 |
FAK |
phosphorylation |
Tyr397 |
human |
Myeloma |
MM1 |
Palmitoyl-cyclic phosphatidic acid (Pal-cPA) |
Associated |
4.0 |
12738990
|
acc1773 |
FAK |
phosphorylation |
Tyr397 |
mouse |
Melanoma |
B16 |
Palmitoyl-cyclic phosphatidic acid (Pal-cPA) |
Associated |
4.0 |
12738990
|
acc1774 |
FOXO1 |
phosphorylation |
Ser256 |
human |
Breast Cancer |
SUM159PT |
Cold atmospheric plasma (CAP) |
Associated |
4.0 |
35637961
|
acc1775 |
FOXO1 |
phosphorylation |
Thr24 |
human |
Colorectal Cancer |
HT29 |
Rapamycin |
Impairing |
5.0 |
20392999
|
acc1776 |
FOXO1 |
phosphorylation |
Thr24 |
human |
Colorectal Cancer |
LS174T |
Rapamycin |
Impairing |
5.0 |
20392999
|
acc1777 |
HER2 |
phosphorylation |
Tyr1248 |
human |
Breast Cancer |
BT474 |
Trastuzumab |
Impairing |
5.0 |
21803025
|
acc1778 |
HER2 |
phosphorylation |
Tyr1248 |
human |
Breast Cancer |
SK-BR-3 |
Trastuzumab |
Impairing |
5.0 |
21803025
|
acc1779 |
EGFR |
phosphorylation |
Tyr845 |
human |
Lung Cancer |
H1299 |
GPNMB |
Impairing |
3.0 |
33706413
|
acc1780 |
GPNMB |
glycosylation |
Asn134 |
human |
Lung Cancer |
H1299 |
GPNMB |
Impairing |
3.0 |
33706413
|
acc1781 |
53BP1 |
phosphorylation |
Ser166 |
human |
Glioblastoma |
U87 |
Ionizing radiation + SB216763 |
Associated |
4.0 |
29328365
|
acc1782 |
53BP1 |
phosphorylation |
Ser166 |
human |
Glioblastoma |
U87 |
Ionising radiation |
Impairing |
4.5 |
29328365
|
acc1783 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Head and Neck Cancer |
Tu212 |
Erlotinib |
Associated |
4.0 |
24019973
|
acc1784 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Head and Neck Cancer |
Tu686 |
Erlotinib |
Associated |
4.0 |
24019973
|
acc1785 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Head and Neck Cancer |
Tu212 |
Erlotinib |
Impairing |
5.0 |
24019973
|
acc1786 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Head and Neck Cancer |
Tu686 |
Erlotinib |
Impairing |
5.0 |
24019973
|
acc1787 |
eIF2alpha |
phosphorylation |
Ser51 |
human |
Breast Cancer |
MCF7 |
Rapalogues |
Enhancing |
5.0 |
24204783
|
acc1788 |
eIF2alpha |
phosphorylation |
Ser51 |
human |
Breast Cancer |
MDA-MB-231 |
Rapalogues |
Enhancing |
5.0 |
24204783
|
acc1789 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Neuroblastoma |
SH-SY5Y |
FK506 |
Associated |
3.0 |
19659461
|
acc1790 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Neuroblastoma |
SH-SY5Y |
Cyclosporine A |
Associated |
3.0 |
19659461
|
acc1791 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Breast Cancer |
MCF7(TamR) |
Tamoxifen |
Associated |
4.0 |
21044952
|
acc1792 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Colorectal Cancer |
HCT116 |
Enzastaurin |
Associated |
4.0 |
16103100
|
acc1793 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Glioblastoma |
U87-MG |
Enzastaurin |
Associated |
4.0 |
16103100
|
acc1794 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Prostate Cancer |
PC3 |
Enzastaurin |
Associated |
4.0 |
16103100
|
acc1795 |
AKT |
phosphorylation |
Thr308 |
human |
Colorectal Cancer |
HCT116 |
Enzastaurin |
Associated |
4.0 |
16103100
|
acc1796 |
AKT |
phosphorylation |
Thr308 |
human |
Glioblastoma |
U87-MG |
Enzastaurin |
Associated |
4.0 |
16103100
|
acc1797 |
AKT |
phosphorylation |
Thr308 |
human |
Prostate Cancer |
PC3 |
Enzastaurin |
Associated |
4.0 |
16103100
|
acc1798 |
GSTP1 |
phosphorylation |
Tyr7 |
human |
Breast Cancer |
SUM 149 |
Cisplatin |
Impairing |
5.0 |
19254954
|
acc1799 |
GSTP1 |
phosphorylation |
Tyr7 |
human |
Glioma |
MGR1 |
Cisplatin |
Impairing |
5.0 |
19254954
|
acc1800 |
GSTP1 |
phosphorylation |
Tyr7 |
human |
Glioma |
MGR3 |
Cisplatin |
Impairing |
5.0 |
19254954
|